DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Drug Metabolism and Disposition Fast Forward
First published on April 12, 2007; DOI: 10.1124/dmd.106.012906

0090-9556/07/3507-1135-1141$20.00
DMD 35:1135-1141, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.106.012906v1
35/7/1135    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Volotinen, M.
Right arrow Articles by Pelkonen, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Volotinen, M.
Right arrow Articles by Pelkonen, O.

Timolol Metabolism in Human Liver Microsomes Is Mediated Principally by CYP2D6

Marjo Volotinen, Miia Turpeinen, Ari Tolonen, Jouko Uusitalo, Jukka Mäenpää, and Olavi Pelkonen

Santen Oy, Tampere, Finland (M.V., J.M.); University of Oulu, Departments of Pharmacology and Toxicology (M.T., O.P.) and Chemistry (A.T.), Oulu, Finland; and Novamass Analytical Ltd., Oulu, Finland (A.T., J.U.)

Timolol has mainly been used topically for the treatment of glaucoma. It has been suggested that the drug is metabolized by cytochrome P450 CYP2D6. The matter has not, however, been extensively studied. The aim here was to tentatively identify timolol metabolites and to determine the P450-associated metabolic and interaction properties of timolol in vitro. Four metabolites were identified, the most abundant being a hydroxy metabolite, M1. The Km value for the formation of M1 was 23.8 µM in human liver microsomes. Metabolism of timolol with recombinant P450s and correlation analysis have confirmed the conception that the drug is metabolized principally by CYP2D6, CYP2C19 being only a minor contributor (<10%) to the intrinsic microsomal clearance. The CYP2D6 inhibitor quinidine proved a potent competitive inhibitor of timolol metabolism, with an in vitro Ki value of 0.08 µM. Fluvoxamine, an inhibitor of CYP2C19, inhibited timolol metabolism to a lesser extent, confirming its minor contribution. Timolol itself did not inhibit CYP2D6-catalyzed dextromethorphan O-demethylation. Judging from the disappearance of timolol in human liver homogenate, the in vivo half-life was extrapolated to be about 3 h, an estimate close to the half-life of about 2 to 5 h observed in vivo. In conclusion, the inhibition of timolol metabolism by quinidine should be taken into account when patients are treated with timolol. However, when plasma timolol concentrations in patients remain low (≤0.2 µg/l), it is suggested that such interaction is of minor clinical relevance.

Address correspondence to: Olavi Pelkonen, Department of Pharmacology and Toxicology, P.O. Box 5000, 90014 University of Oulu, Finland. E-mail: olavi.pelkonen{at}oulu.fi




This article has been cited by other articles:


Home page
 IOVSHome page
M. Volotinen, J. Maenpaa, E. Kankuri, O. Oksala, O. Pelkonen, M. Nakajima, T. Yokoi, and J. Hakkola
Expression of Cytochrome P450 (CYP) Enzymes in Human Nonpigmented Ciliary Epithelial Cells: Induction of CYP1B1 Expression by TCDD
Invest. Ophthalmol. Vis. Sci., July 1, 2009; 50(7): 3099 - 3105.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.